El-Husseini, Zaid W.
Khalenkow, Dmitry
Lan, Andy
van der Molen, Thys
Brightling, Chris
Papi, Alberto
Rabe, Klaus F.
Siddiqui, Salman
Singh, Dave
Kraft, Monica
Beghe, Bianca
van den Berge, Maarten
van Gosliga, Djoke
Nawijn, Martijn C.
Rose-John, Stefan
Koppelman, Gerard H.
Gosens, Reinoud
Funding for this research was provided by:
Stichting De Cock-Hadders (2022-33)
European Union’s Horizon 2020 research (754425)
Article History
Received: 22 September 2023
Accepted: 27 November 2023
First Online: 7 December 2023
Declarations
:
: The study protocol was consistent with the Research Code of the University Medical Center Groningen [research code UMCG (umcgresearch.org)] and national ethical and professional guidelines [Code of conduct for Health Research (only in Dutch): Gedragscode-Gezondheidsonderzoek-2022.pdf (coreon.org)]. Lung tissues used in this study were derived from leftover lung material after lung surgery from archival materials that are exempt from consent in compliance with applicable laws and regulations [Dutch laws: Medical Treatment Agreement Act (WGBO) art 458/GDPR art 9/UAVG art 24]. This material was not subject to the Medical Research Human Subjects Act in the Netherlands, and, therefore, an ethics waiver was provided by the Medical Ethical Committee of the University Medical Center Groningen. All samples and clinical information were coded before experiments were performed, blinding all directly identifying information to the investigators.
: Not applicable.
: Mr. Elhusseini has nothing to disclose. Dr. Gosens and Dr. Koppelman reports grants from Marie Sklodowska-Curie reports grants from Marie Sklodowska-Curie during the conduct of the study; grants from TEVA the Netherlands, GSK, Lung Foundation of the Netherlands, VERTEX, UBBO EMMIUS foundation, TETRI Foundation, and ZON-MW outside the submitted work; and GHK participated in advisory board meetings for GSK, Astra Zeneca and PURE-IMS (money to institution). Dr. Rose-John has acted as a consultant and speaker for AbbVie, Chugai, Genentech Roche, Regeneron, Pfizer, and Sanofi. He also declares that he is an inventor on patents owned by CONARIS Research Institute, which develops the sgp130Fc protein Olamkicept together with Ferring Pharmaceuticals and I-Mab Biopharma S.R.-J. has stock ownership in CONARIS. Dr. Kraft has received consultant and speaking fees for Sanofi-Regeneron, AstraZeneca, Chiesi and GSK. Dr. Nawijn, Dr. Khalenkow, Mr. Lan, Ms. Gosliga, Dr. van der Molen, Dr. Brightling, Dr. Beghé, Dr. Papi, Dr. Rabe, Dr. Siddiqui, and Dr. Singh have nothing to disclose.